Browsing Tag
HealthCare Royalty
5 posts
OPKO Health (Nasdaq: OPK) raises $125m against mazdutide royalties as GLP-1 financing strategy deepens
OPKO Health raises $125 million against mazdutide royalties. Read how the KKR-linked financing reshapes OPK’s GLP-1 capital strategy.
Spero Therapeutics (Nasdaq: SPRO) pivots to immunology after Utebzi approval and $105m financing
Spero Therapeutics uses Utebzi royalties to fund an Innovent immunology pivot. Read how SPRO’s cash runway, CD40L bet and stock discount fit together.
BridgeBio raises $1bn in preferred equity to fund rare disease product launches
BridgeBio’s $1 billion preferred equity raise strengthens BBIO’s balance sheet as Attruby grows and three rare disease launches approach.
REGENXBIO monetizes gene therapy royalties in $250m deal with HCRx
REGENXBIO advances strategic funding deal with Healthcare Royalty to monetize Zolgensma and pipeline royalties while preserving upside from NAV platform assets and AbbVie/Nippon Shinyaku partnerships.
Liquidia Corporation shares soar 13% following dual financing announcement
Liquidia Corporation experienced a dramatic surge in its stock price, climbing 13% to $10.02, following the announcement of…